Company / Interest Expense
Tarsus Pharmaceuticals, Inc. Interest Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$8.9M
FY2025
5-year range
$0 / $8.9M
FY2021-FY2025
Trend
+13.8%
vs FY2024
Sector context
#30 of 44
Health Care
What the data says
At $9M, Tarsus Pharmaceuticals, Inc.'s interest expense ranks #15 of 44 in the Health Care sector. Interest Expense has increased for 3 consecutive years, from $0 in FY2022 to $9M in FY2025.
Based on SEC 10-K filings.
$9M in FY2025.
Increased from $3M to $9M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#15 of 44 in Health CareTop 32% of 44This company $8.9M Sector average $291.0M
▼
-96.9% below sector average
Key checks
Key Insights
- In FY2025, interest expense increased 13.8% year-over-year.
- Ranks #30 out of 44 companies in the Health Care sector.
- Lowest interest expense in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.9M | +13.8% |
| FY2024 | $7.8M | +134.6% |
| FY2023 | $3.3M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026